<DOC>
	<DOCNO>NCT02223884</DOCNO>
	<brief_summary>This phase II , single-arm , single-center study assess efficacy weekly docetaxel plus carboplatin second-line treatment malignant melanoma ( unresectable metastatic ) fail dacarbazine temozolomide contain therapy . The primary end point overall response rate accord RECIST 1.1 criterion assess use CT MRI secondary end point include disease control rate , progression free survival , overall survival safety .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Docetaxel Carboplatin Metastatic Malignant Melanoma Failed First-Line Dacabazine Temozolomide Contained Therapy</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients histologically prove malignant melanoma ( recur metastatic ) progress receive least one cycle regimen contain dacarbazine temozolomide advance set Measurable disease ( RECIST ) ECOG performance 02 Adequate organ function Total bilirubin &lt; 1.5N ; ASAT ALAT &lt; 2.5N Serum Creatinin &lt; 1.5N ANC ≥ 1,500/mm³ ( GCSF allow ) Platelets ≥ 100,000/mm³ Hb ≥ 9.0 g/dL Life expectancy least 12 week Signed Written Informed Consent Symptomatic brain metastasis Previous history treatment taxane platinum agent contain chemotherapy Previous major surgery within 2 week start trial , failure recover surgery Previous history malignancy within 5 year except cured skin basal cell carcinoma cure insitu cervix cancer Other severe medical condition ( infection , uncontrolled hypertension , heart failure , MI history within 6 month ) Sensitivity platinum agent docetaxel Uncontrolled seizure Women pregnant nursing Alcohol drug abuser</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Malignant melanoma , second-line treatment , docetaxel , carboplatin</keyword>
</DOC>